GlaxoSmithKline CEO: Chin up, investors. Dividend’s safe, and Novartis deal awaits

Carly Helfand

's shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty to look forward to, CEO Andrew Witty reminded them on Thursday.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS